Julio Núñez
A5039483633- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Acute Myocardial Infarction Research
- Coronary Interventions and Diagnostics
- Diabetes Treatment and Management
- Cardiac pacing and defibrillation studies
- Potassium and Related Disorders
- Cardiac Structural Anomalies and Repair
- Cardiac electrophysiology and arrhythmias
- Cardiac Valve Diseases and Treatments
- Advanced MRI Techniques and Applications
- Atrial Fibrillation Management and Outcomes
- Cardiovascular and exercise physiology
- Blood Pressure and Hypertension Studies
- Erythropoietin and Anemia Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Dialysis and Renal Disease Management
- Electrolyte and hormonal disorders
- Mechanical Circulatory Support Devices
- Frailty in Older Adults
- Acute Kidney Injury Research
- Cardiac Health and Mental Health
- Health Systems, Economic Evaluations, Quality of Life
- Lipoproteins and Cardiovascular Health
Centro de Investigación en Red en Enfermedades Cardiovasculares
2017-2025
Universitat de València
2016-2025
Hospital Clínico Universitario de Valencia
2016-2025
Centro de Investigación Biomédica en Red
2017-2025
INCLIVA Health Research Institute
2016-2025
Spanish Society of Hematology and Hemotherapy
2025
Instituto de Salud Carlos III
2017-2024
University of Missouri–Kansas City
2023-2024
Hospital Universitario de Gran Canaria Doctor Negrín
2024
Hospital Universitario Virgen de la Arrixaca
2024
BackgroundHeart failure with preserved ejection fraction is increasing in prevalence and associated a high symptom burden functional impairment, especially persons obesity. No therapies have been approved to target obesity-related heart fraction.MethodsWe randomly assigned 529 patients who had body-mass index (the weight kilograms divided by the square of height meters) 30 or higher receive once-weekly semaglutide (2.4 mg) placebo for 52 weeks. The dual primary end points were change from...
Alcoholic cardiomyopathy (ACM) is defined by a dilated and impaired left ventricle due to chronic excess alcohol consumption. It largely unknown which factors determine cardiac toxicity on exposure alcohol. This study sought evaluate the role of variation in cardiomyopathy-associated genes pathophysiology ACM, examine effects intake genotype (DCM) severity. The authors characterized 141 ACM cases, 716 DCM 445 healthy volunteers. compared prevalence rare, protein-altering variants 9...
Obesity and type 2 diabetes are prevalent in patients with heart failure preserved ejection fraction characterized by a high symptom burden. No approved therapies specifically target obesity-related persons diabetes.
Chronotropic incompetence has shown to be associated with a decrease in exercise capacity heart failure preserved ejection fraction (HFpEF), yet β-blockers are commonly used HFpEF despite the lack of robust evidence. This study aimed evaluate effect β-blocker withdrawal on peak oxygen consumption (peak Vo2) patients and chronotropic incompetence. is multicenter, randomized, investigator-blinded, crossover clinical trial consisting 2 treatment periods weeks separated by washout period weeks....
In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function reduced body weight in patients with obesity phenotype of heart failure preserved ejection fraction (HFpEF). This prespecified analysis examined effects on dual primary endpoints (change Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) weight) confirmatory secondary 6-minute walk distance (6MWD), hierarchical composite (death, HF events, change KCCQ-CSS 6MWD)...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy controlling glycaemia inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs), namely nausea, vomiting, diarrhoea and/or constipation. To minimize severity duration, healthcare providers (HCPs) patients must be aware of appropriate measures to follow while undergoing treatment. An expert panel comprising endocrinologists,...
To our knowledge, no randomized clinical trial has compared the invasive and conservative strategies in frail, older patients with non-ST-segment elevation acute myocardial infarction (NSTEMI).
Increasing the patient's heart rate (HR) has emerged as a therapeutic option in patients with failure preserved ejection fraction (HFpEF). However, evidence is conflicting, and profile of who benefit most from this strategy remains unclear.
Obesity is associated with adverse cardiac remodeling and a key driver for the development progression of heart failure (HF). Once-weekly semaglutide (2.4 mg) has been shown to improve HF-related symptoms physical limitations, body weight, exercise function in patients obesity-related preserved ejection fraction (HFpEF), but effects on structure this population remain unknown.
An interatrial shunt may provide an autoregulatory mechanism to decrease left atrial pressure and improve heart failure (HF) symptoms prognosis.
Background: The prognostic value of long-term potassium monitoring and dynamics in heart failure has not been characterized completely. We sought to determine the association between serum values collected at follow-up with all-cause mortality a prospective consecutive cohort patients discharged from previous acute admission. Methods: Serum was measured every physician-patient encounter, including hospital admissions ambulatory settings. multivariable-adjusted assessed by using comprehensive...